A detailed history of Gladius Capital Management LP transactions in Organon & Co. stock. As of the latest transaction made, Gladius Capital Management LP holds 1,456 shares of OGN stock, worth $23,383. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,456
Previous 1,456 -0.0%
Holding current value
$23,383
Previous $27,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$18.65 - $23.03 $1,510 - $1,865
-81 Reduced 5.27%
1,456 $27,000
Q2 2024

Jul 18, 2024

SELL
$17.45 - $21.96 $9,248 - $11,638
-530 Reduced 25.64%
1,537 $31,000
Q1 2024

May 14, 2024

SELL
$13.78 - $18.8 $1,502 - $2,049
-109 Reduced 5.01%
2,067 $38,000
Q4 2023

Feb 07, 2024

BUY
$10.95 - $17.32 $9,395 - $14,860
858 Added 65.1%
2,176 $31,000
Q3 2023

Dec 18, 2023

SELL
$16.59 - $23.77 $912 - $1,307
-55 Reduced 4.01%
1,318 $22,000
Q3 2023

Oct 10, 2023

SELL
$16.59 - $23.77 $912 - $1,307
-55 Reduced 4.01%
1,318 $23,000
Q2 2023

Dec 18, 2023

BUY
$19.27 - $24.63 $1,059 - $1,354
55 Added 4.17%
1,373 $28,000
Q2 2023

Aug 08, 2023

BUY
$19.27 - $24.63 $3,430 - $4,384
178 Added 14.9%
1,373 $29,000
Q1 2023

Dec 18, 2023

SELL
$21.42 - $32.08 $2,634 - $3,945
-123 Reduced 9.33%
1,195 $28,000
Q1 2023

May 09, 2023

SELL
$21.42 - $32.08 $4,905 - $7,346
-229 Reduced 16.08%
1,195 $29,000
Q4 2022

Dec 18, 2023

BUY
$23.31 - $28.61 $2,470 - $3,032
106 Added 8.04%
1,424 $39,000
Q4 2022

Feb 02, 2023

BUY
$23.31 - $28.61 $4,149 - $5,092
178 Added 14.29%
1,424 $40,000
Q3 2022

Nov 14, 2022

BUY
$23.4 - $34.25 $29,156 - $42,675
1,246 New
1,246 $30,000

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $4.08B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Gladius Capital Management LP Portfolio

Follow Gladius Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Gladius Capital Management LP with notifications on news.